Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like 50+ Valeant Sales Reps May Have Jumped Ship to Synergy Pharma February 23, 2017 New Study Indicates DNA Plays Role in Gender Identity March 18, 2018 Cardiome Pharma Corp. Announces Voting Results June 22, 2017
